Premium
Cystine‐glutamate antiporter xCT as a therapeutic target for cancer
Author(s) -
Liu Lin,
Liu Rui,
Liu Yi,
Li Guanghui,
Chen Qing,
Liu Xiaodong,
Ma Shumei
Publication year - 2021
Publication title -
cell biochemistry and function
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.933
H-Index - 61
eISSN - 1099-0844
pISSN - 0263-6484
DOI - 10.1002/cbf.3581
Subject(s) - antiporter , cystine , transporter , chemistry , glutathione , solute carrier family , glutamate receptor , amino acid , biochemistry , glutamic acid , amino acid transporter , cancer cell , oxidative stress , excitatory amino acid transporter , microbiology and biotechnology , cancer , biology , cysteine , gene , membrane , enzyme , genetics , receptor
Cystine/glutamic acid reverse transporter (System X c − ), a member of the amino acid transporter family, consists of two subunits, light chain xCT and heavy chain 4F2hc. xCT is the cystine/glutamate antiporter solute carrier family 7 member 11 (SLC7A11), which promotes cystine uptake and glutathione biosynthetic, thus protecting against oxidative stress and ferroptosis. Studies have confirmed that xCT is highly expressed in a variety of tumour and is associated with tumour proliferation, invasion, metastasis, drug resistance and ferroptosis, and can be used as a potential target for tumour treatment. This review provides insights into the biological effects of xCT and contribute to the development of new xCT‐based strategies.